At the end of July, the Supreme Court of Israel issued a judgment giving local consumers the right to submit class-action suits against dominant companies in case of exorbitantly high prices.
…
The Netherlands Authority for the Consumer and Markets’ ("ACM") announced focus on drug price developments has finally come to a tangible enforcement result: a fine of almost EUR 20 million imposed…
We are happy to announce the new International Law Talk Podcast episode on EU competition law developments in the pharmaceutical sector. And this one is twice as good! Not only are we discussing both…
Back in April 2017, The Times ran a story detailing how a drug giant had a “secret plan” to destroy a cancer medicine unless large price rises were agreed to by national purchasing authorities. A…
What are commitments?
The recent effort by the Commission to settle the Aspen case suggests that commitment decisions are the preferred route to settle complex excessive pricing cases at EU-level…
The Turkish Competition Authority (“TCA”) on March 23, 2020 gave its heads up to undertakings that it was “closely following the price increases”, which it referred to as “opportunistic” during the…
In April 2020, The Turkish Competition Authority (“TCA”) initiated two separate preliminary inquiries in the protective face mask and retail sectors. These inquiries are a part of the TCA’s current…
Introduction
While the world is dealing with novel coronavirus pandemic, many countries resorted to protectionist measures in order to preserve the quality of social life and stability of the economy…
Summary
On 10 March 2020 the Court of Appeal upheld the Competition Appeal Tribunal’s (CAT) quashing of the Competition and Markets Authority’s (CMA) decision that Pfizer and Flynn Pharma (Flynn)…
